Kane Biotech to Present revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Fall Conference

Core Insights - Kane Biotech Inc. is presenting clinical data on wound healing at the SAWC Fall conference, showcasing the effectiveness of their revyve Antimicrobial Wound Gel in treating complex wounds over two years old [1][4]. Group 1: Clinical Data Presentation - The first presentation discusses the clinical use of revyve Antimicrobial Wound Gel on a two-year-old non-healing Stage 4 sacral ulcer, resulting in pain reduction from 10/10 to 0 and a decrease in wound size over three weeks [2]. - The second presentation highlights the use of revyve Antimicrobial Wound Gel combined with vibrational debridement on a non-healing venous leg ulcer, achieving a 60% reduction in wound size over eight weeks and pain levels decreasing from 5/10 to 0 [3]. Group 2: Product Information - Kane Biotech's revyve Antimicrobial Wound Gel and Wound Gel Spray have received FDA 510(k) clearance and will be exhibited at the conference, with the Interim CEO meeting potential US distributors [4][6]. - The revyve products are designed to disrupt biofilms and improve healing outcomes, addressing antibiotic resistance in wounds, and are also approved by Health Canada [7].